Introduction
Multiple myeloma (MM) remains an incurable clonal B lymphoid neoplasm of plasma cells, second only to non-Hodgkin's lymphoma in incidence 1 . Despite significant initial responses to chemotherapy, >90% of patients with MM relapse with resistant disease 2 ,
underscoring the need to identify novel therapeutic targets that affect myeloma survival and resistance pathways. Given that MM cells are critically dependent on normal elements of the bone marrow stroma for cell growth and survival, these interactions are attractive targets. One such interaction is stromal production of soluble growth factors, such as IL-6 and TRANCE 1, 3 .
Another important set of interactions involves direct myeloma cell contact with extracellular matrix (ECM) and/or stromal cells. Such direct contact upregulates stromal cell IL-6 and VEGF production, induces NFκB signaling, drop myeloma cells out of cell cycle and enhances resistance to chemotherapy [4] [5] [6] . However, the specific molecular (e.g. integrins 4, 7 ) and cellular components (e.g. osteoclasts 8 ) of these direct interactions within the complex bone marrow microenvironment are only beginning to be described. As important, the characteristic progression of myeloma to stromal-independence marks a clinically worse disease 9 , yet the mechanisms that underlie this transition are also poorly understood.
Identification of pro-survival receptors typically expressed on myeloma cells may point to the stromal cells expressing the receptor ligands. One potential receptor is CD28. CD28 has a restricted lineage expression, found predominantly on T cells but also on normal plasma cells, primary myeloma isolates and myeloma cell lines at levels comparable to T cells [10] [11] [12] [13] . In T cells, CD28 receptor activation occurs following binding to its ligands, CD80 (B7-1) and CD86 (B7-2), which are expressed predominantly on professional antigen presenting cells (APC), and in particular dendritic cells (DC) 14 . The signaling pathways downstream of the CD28 receptor in T only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From cells include PI-3 kinase PDK1 Akt and Vav Rac1/Cdc42 MEKK (both which regulate NFκB activation) 15 -and importantly, in myeloma cells PI3K/Akt signaling transduces the antiapoptotic effects of IL-6 and insulin-like growth factor 1 (IGF-1) 16 , and for IGF-1 involves sustained activation of NFκB 17 . Functionally, CD28 delivers the costimulatory signal that in conjunction with T cell receptor signaling results in augmented T cell proliferation, effector function 18, 19 and enhanced survival via upregulation of anti-apoptotic gene bcl-x L 20 and more efficient glucose metabolism 21 .
In contrast to T cells, little is known about CD28 function in myeloma cells. Clinically however, CD28 expression highly correlates with myeloma disease progression, such that high CD28 expression is seen in 26% of newly diagnosed myelomas, 59% of medullary relapses, 93%
of extramedullary relapses and 100% of secondary plasma cell leukemias (including nearly all the human and murine MM cell lines) 12, 22 . Moreover, myeloma cell expression of CD28 in newly diagnosed patients is a major prognostic predictor of poor clinical outcome following high dose chemotherapy 23, 24 . These clinical findings suggest that CD28 express helps these MM cells better survive treatment and result in their selective outgrowth. Additionally, the possibility that CD28 is involved in the progression to stroma-independent MM is supported by observations that primary CD28 + myelomas co-express CD86 (10/10 patient samples in 12 ) and that CD86 + myelomas have a significantly poorer prognosis 25 . 
Materials and Methods
The University of Miami IRB approval has been obtained for the sample collection protocols for obtaining the primary myeloma samples. viable cell numbers were enumerated by quadruplicate cell counts using trypan blue.
Cell proliferation assays were done in 0.1% FCS. 0.5 µCi/well [methyl-3 H] thymidine was added for the final 18 hours of culture, and incorporation measured using the Beta Plate scintillation counting system (Wallac Inc., Gaithersburg, MD) 37 . All conditions were performed in triplicates, and data is represented as the mean counts ± 1 SD.
Myeloma-DC coculture
K562 and KG1 were differentiated into dendritic cells/myeloid APC as previously described 37, 38 . Briefly, cells were cultured in media alone or differentiated for 5-7 days with PMA (10 ng/ml, Sigma, St. Louis, MO) + TNF-α (10 ng/ml, R&D Systems, Minneapolis, MN).
Primary monocytes were enriched from the peripheral blood MNC of normal donors (in IRB approved protocols) by plastic adherence and differentiated into DC using GM-CSF (1000 U/ml, Immunex, Seattle, WA) and IL-4 (1000 U/ml, R&D Systems, Minneapolis, MN) for 8 days + TNF-α (20 ng/ml) for the last four days of culture 39 . DC were then washed, irradiated at 3,000R 
Statistical analysis
Pair-wise comparisons were conducted using Student's t Test.
Results

Myeloma cell express CD28 and CD86.
As seen in Figure 1A (top panels), CD28 is expressed on three human myeloma cell lines (RPMI 8226 (8226), MM.1S and U266) at levels slightly lower than the cytotoxic T cell line YT.
CD28 is also expressed on primary MM cells purified from bone marrow aspirates of patients with relapsed disease (Fig. 1A , lower panels), and also on the infiltrating myeloma cells from patients with extramedullary intramuscular plasmacytomas (Fig. 1B) . As suggested by previous studies, all three MM cell lines also co-expressed CD86 but not CD80 (Fig. 1C) , which is more clearly seen using indirect staining with CTLA4Ig.
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CD28 triggers PI3-kinase signaling in myeloma cells.
In T cells, one pathway downstream of the CD28 receptor is PI3K/Akt activation 41 , and in myeloma cells the pro-survival effects of IGF-1 are transduced through PI3K/Akt signaling and downstream NFκB activation 16, 17 . To assess whether CD28 activation can also trigger this pathway in MM cells, PI3K activation was characterized via ELISA based measurement of the phosphorylated (activated) p85 subunit of PI3K following activation with the anti-CD28 mAb 9.3. As can be seen in Fig. 2 , CD28 activation results in rapid (by 5 minutes) detection of phospho-p85 in all three MM cell lines, with sustained levels out to 24 hrs. This is consistent with previous studies demonstrating association of p85 to the CD28 receptor in myeloma cells 27 .
Activation of downstream NFκB signaling.
To determine if CD28-induced PI3K triggered downstream NFκB signaling, we initially sought evidence for IκBα degradation. As seen in Figure 3A , antibody-mediated activation of CD28 alone results in reduction of cellular IκBα in both 8226 and U266. The anti-apoptotic protein Bcl-x L is not upregulated, consistent with previous reports that CD28 activation alone does not upregulate this expression in T cells 20 . To more directly assess CD28-induced NFκB signaling, levels of free nuclear NFκB dimers were measured by electromobility gel shift assay.
CD28 activation (using either bead bound or soluble mAb (not shown)) increases total nuclear NFκB binding in both U266 and 8226 (Fig. 3B ). Supershift assays for NFκB family members demonstrate increased levels of p50, p65, Rel B and c-Rel, suggesting that both the canonical (p65, p50/p52 homodimers) and non-canonical (RelB) pathways are being activated. In contrast, binding of CD86 with CD28Ig has no effect on NFκB signaling (Fig. 3C ), indicating that 9.3's effects are not paradoxically due to the blocking of a myeloma CD28-myeloma CD86
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CD28 downmodulates myeloma cell proliferation.
The ability of CD28 to co-stimulate T cell proliferation and survival can be segregated into 2 independent downstream signaling pathways, with PI3K being essential for survival while factors binding the C-terminal proline motifs for proliferation and cytokine responses 43 . We next assessed the effect CD28 activation on myeloma cell proliferation, which were done in low FCS conditions (0.1%) as normal serum contains IGF-1 that may mask a CD28 signal. In comparison to 8226, U266 and MM.1S cultured with control (uncoated) beads, cell proliferation was significantly suppressed by culture with 9.3 coated beads. In comparison, the 9.3 coated beads had no effect on the CD28-negative cell line K562.
CD28 activation enhances myeloma cell survival
Pro-survival factors IGF-1 and IL-6 activate NFκB 44 , suggesting that CD28 may also support myeloma cell survival (we (data not shown) and others have found that CD28 does not induce IL-6 secretion in MM cells). As serum contains sufficient IGF-1 to prevent apoptosis 45 , we asked if withdrawl of serum induces cell death in 8226 and MM.1S, and whether CD28 activation could provide substitute survival signals. As seen in Figure 5A , serum starvation results in substantial cell death in both 8226 and MM.1S by 48 hrs that could be abrogated in only.
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We next examined whether CD28 activation could protect against death induced by dexamethasone (dex), a more defined death signal and clinically relevant agent. To minimize the possibility of serum IGF-1 masking a CD28 pro-survival signal, we conducted these assays in low serum conditions (0.1%, which alone did not affect the viability of our cell lines). As seen in Fig. 5B , dex effectively killed all 3 MM cell lines, and anti-CD28 mAb-mediated activation resulted in significant protection against this dex-induced death.
Whether CD28 activation also had pro-survival effects in primary myeloma cells was examined in cells purified from 3 patient samples (relapsed disease), with the resulting cell populations >90% positive for plasma cell marker CD138 (all 3 samples were CD28 positive). The purified MM cells were then cultured in 10% serum (Fig. 5C , left, for patient sample 1) or without serum (Fig. 5C , right) plus/minus anti-CD28 mAb for 24h. Serum starvation was used as all the patients were clinically dexamethasone resistant. While primary myeloma cells fared reasonably well in 10% FCS (and were largely unaffected by anti-CD28 mAb -which also demonstrates that the mAb was not inducing proliferation), there was a considerable loss of viable cells when serum was withdrawn. Consistent with our cell line findings, activation of CD28 substantially improved myeloma cell survival.
Dendritic cells associate with myeloma cells in vitro and in vivo
Biologically relevant activation of CD28 in myeloma cells likely occurs the same way it does in T cells, namely by direct cell-cell contact with CD80/CD86 cells (especially APC).
Given previous studies have found dendritic cells in myeloma/plasmacytoma infiltrates 34,46 , we only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From first examined whether DC could be preferentially found within myeloma infiltrates in patient bone marrow biopsies. CD138 staining was used to identify myeloma cells, and fascin staining plus morphology to identify DC 34 . Previous studies have found that the expression of the actin bundling protein fascin is very specific for DC in paraffin-embedded tissue [47] [48] [49] , and superior to HLA-DR or S100 staining for distinguishing DC from tissue macrophages 50 . We found that 4 of 5 patients with relapsed myeloma had numerous fascin + cells with DC morphology within the CD138 + myeloma cell infiltrates, while the fifth patient (pt. 90) had fewer but detectable numbers of DC (Table 1) . These fascin + cells were predominantly localized within the CD138 + cell infiltrates, as non-infiltrated areas of bone marrow within the same marrow section had significantly fewer fascin + cells (except for patient 90, who had the same low number in both areas). Figure 6 demonstrates the numerous fascin + cell processes and less frequent cell bodies (right) that could be readily found interdigitating between CD138 + myeloma cells (left). Because fascin expression positively correlates with DC maturation 50 , these findings suggest that myeloma-infiltrating DC have the high CD80/CD86 expression typical of mature DC.
Consistent with this, CD83 staining yields similar findings (not shown).
Coculture with dendritic cells modulates myeloma cell proliferation and survival
To characterize the possible effects of DC interaction on myeloma cells, we initially used myeloid DC derived from human CD34 + leukemia cell lines (KG1 38 and K562 37 ). Cell-line derived DC are a more homogenous population than primary monocyte-derived DC, with less variability due to progenitor purity, maturation differences, etc. We and others have also shown that these myeloid blasts are not immunostimulatory when undifferentiated, but when differentiated with cytokines or phorbol esters (PMA) result in antigen-presenting cells that have only.
For . We first characterized the effect of DC on myeloma cell proliferation. Proliferation of 8226 ( Figure 7A , left panel) and U266 ( Figure 7A, right panel) was not affected when cocultured with irradiated, undifferentiated K562. However, similar to activation with anti-CD28 mAb, coculture with K562 -differentiated to DC by PMA or PMA+TNF-α (TNF addition drives further DC maturation) significantly downmodulated the proliferation of 8226 and U266 proliferation. KG1 yielded the same results (below). It is unlikely that this decrease is due residual PMA carryover, as PMA is not detected in other sensitive assays (e.g. T cell proliferation) and that PMA alone has no effect on 8226 or U266 proliferation (our data not shown and 27 ). Initial cell cycle analysis of 8226 suggests the inhibition of proliferation is via a G 0 /G 1 arrest when cultured with K562-derived DC, but not with undifferentiated K562 (Fig. 7B) . To formally exclude the induction of MM cell death as the cause of decreased proliferation, CSFE-labeled 8226 assayed for cell viability (by PI staining)
after coculture with K562-derived DC. After 24 hrs of coculture there are very few PI-positive dead cells in either the CFSE + 8226 or CFSE -K562-DC populations (Fig. 7C) .
Given the DC-MM interaction involves multiple receptor-ligand bindings that could have cellular effects, the specific contribution of CD28 on the modulation of proliferation was assessed by blocking CD80/CD86 with the chimeric CD28 receptor-immunoglobulin Fc molecule CD28-Ig. As seen in Figure 7D , CD28-Ig reversed the inhibition of 8226 proliferation induced by co-culture with DC derived from KG1. Similar results were obtained with U266 and
MM.1S (not shown).
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Although we have previously shown that cell line-derived DC are very similar to DC derived from normal progenitors, it is formally possible that these DC have aberrant properties in their interaction with myeloma cells. To address this, 8226 were cocultured with normal monocyte-derived DC (mo-DC) 39 . In addition, we asked if immature DC (iDC, differentiated with GM-CSF + IL-4) affected myeloma cell proliferation differently than mature DC (mDC, GM-CSF +IL-4 + TNF-α). Immature DC have lower expression of costimulatory ligands than mature DC and are less effective at activating T cells 58 , and would be predicted to be less effective in suppressing myeloma proliferation. As seen in Figure 7E , both iDC and mDC significantly downmodulate 8226 proliferation at cell ratios of 1:1. mDC appear to be more potent as they can do this at lower DC:myeloma cell ratios than iDC, which would be consistent with greater CD80/CD86 expression.
To assess whether DC can also transduce a survival signal similar to anti-CD28 mAb, 8226 were cultured alone, with undifferentiated K562, or K562-derived DC in 100 µM dexamethasone (Fig. 7F ). Similar to our results with antibody-mediated activation, co-culture with DC doubles the viability of 8226 vs. myeloma cells alone or plus DC precursors.
Discussion
Consistent with the clinical observation that CD28 expression on myeloma cells correlates with poor prognosis and disease progression, we have found that CD28 activation induces PI3K and NFκB signaling in myeloma cells, and delivers both anti-proliferative and prosurvival signals. Although the intracellular signaling pathways downstream of CD28 have not been well described in myeloma cells, CD28 signaling in T cells induces PI3-kinase activation 15 and significantly augments NFκB activation 59 in combination with mitogen, while superonly.
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Our findings and those of others 27 thus suggest that at least one CD28 signaling pathway is the same in myeloma cells as it is in T cells, namely CD28 PI-3 kinase PDK-1 Akt IκB .
The observation that PI-3K activation of Akt and NFκB is induced by IGF-1 (an established survival factor for myeloma) 16 ,17 further supports a similar survival signal transduced by CD28.
Interestingly, the mammalian target of rapamycin (mTOR) is a central downstream component of Akt signaling, and inhibition by rapamycin both inhibits CD28-mediated mTOR activation in T cells 61 and sensitizes cells to dexamethasone-induced apoptosis in myeloma 62 . Finally, NFκB signaling itself (separate from any upstream signaling pathway) has been clearly shown to enhance myeloma survival 44, 63 , and all these data together support a pro-survival function of CD28 in myeloma.
Despite the similarities in intracellular signaling, we find significant differences in CD28 activation in myeloma vs. T cells. First, a synchronous antigen receptor "signal 1" that is required for CD28 costimulation in T cells appears unnecessary in myeloma cells. Myeloma don't express an antigen receptor, and attempts to define an alternative signal 1 (e.g. IL-6, PKC agonists 22, 27 ) that is costimulated by CD28 have been equivocal. However even in T cells, CD28 can signal in the absence of a concurrent TCR signal 15, 64 , and super-agonistic anti-CD28
antibodies can activate T cells without a signal 1 60 . Thus it is possible that CD28 activation alone induces cellular responses in myeloma because it is triggered at a lower threshold.
Alternatively, there may be less negative regulation of downstream signaling (e.g. PI-3K by PTEN), resulting in transduction of a comparatively larger signal in myeloma vs. T cells.
A second difference is the effect of CD28 on proliferation, with augmentation in T cells and downmodulation in myeloma cells. Our findings are consistent with previous studies only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From demonstrating that soluble anti-CD28 mAb 9.3 (the same as used in our studies) could suppress the proliferation of the MER myeloma cell line by 50% 65 , as well as a recent study using another anti-CD28 mAb 32 . Although the reasons for this MM -T difference are unclear, it has been shown in T cells that the ability of CD28 to augment proliferation and survival can be segregated into 2 downstream signaling pathways 43 . It is possible that myeloma cells lack the downstream pathways involved in proliferation while retaining the pro-survival pathway, and pro-survival signals by themselves can negatively regulate cell cycle progression 5, 6, 66 . Another possibility is that CD28 in myeloma cells does not elicit autocrine secretion of proliferative cytokines, whereas CD28-induced autocrine secretion of IL-2 is a major factor driving T cell proliferation.
Interestingly, the G 1 arrest we find for CD28 has also been reported in myeloma cells following integrin-mediated adhesion (involving p27 kip1 ), which similarly results in induction of NFκB, decreased proliferation, and enhanced survival/resistance to chemotherapeutic agents [4] [5] [6] . These latter studies also suggest that the decreased proliferation plays a significant role in cell adhesion mediated drug resistance (CAM-DR), protecting MM cells from chemotherapies that target cycling cells.
In addition to defining differences between myeloma and T cells, our findings also stand in contrast to some previous studies in myeloma that have found variable effects of CD28 activation on proliferation and survival, including a recent report of the induction of MM cell apoptosis by anti-CD28 mAb 32 . There are potentially several technical variables that may underlie these differences. First, the different anti-CD28 antibodies may differ in their agonistic or antagonistic/blocking effects. Second, our survival studies were done in no/low serum conditions, whereas previous studies were done in 10% serum. It is possible that in the higher and that CD86 + myelomas have a significantly worse prognosis 12, 25 . Similarly, we and others 27, 67 have found that myeloma cell lines typically co-express CD28 and CD86, although these latter two reports are contradictory as to whether autocrine CD28 activation is occurring. The second possibility is that CD28 activation in myeloma occurs the same way it does on T cells, namely by direct contact with CD80/CD86 + APC. In addition to CD80/CD86 expression, professional APC have specialized ability to directly interact with other immune cells that includes the expression of appropriate adhesion molecules and chemoattractant chemokines. This is particularly true for DC 58 . There is considerable evidence that DC are directly involved in the survival, proliferation and differentiation of normal B cells and plasma cells. These include DC expression of IL-6 68, 69 , that DC and B cells form clusters in vitro and in vivo 70 , that this direct interaction provides B cells with proliferation and survival signals 71 , and drives their differentiation to plasma cells [72] [73] [74] . Recent studies have found that dendritic cells enhance plasmablast survival and differentiation, in part through secretion of APRIL and/or BAFF 75 .
And very recently it has been shown that DC support the clonogenicity of human MM cells 76 . It seems likely that this advantageous interaction is maintained by transformed plasma cells, and only.
For may also have effects on any myeloma-DC interaction. Along these lines it is interesting to note that both thalidomide and bortezomib, which have significant activity in myeloma, have been shown to modulate DC function 78, 79 and induce DC apoptosis 80 .
For + cell infiltrates were first identified, and infiltrated (myeloma) and non-infiltrated areas (normal) were then reexamined for fascin staining on serial sections. The number of fascin-positive cell bodies with dendritic projections (excluding capillary endothelial cells) were counted per high powered field (1000X), and averaged for 5 fields. For all five patients combined, p<0.00001 comparing the number of DC in the CD138 + vs. CD138 -areas.
